Pay in 4 interest-free payments of $6.54 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
the peptide has been shown to promote the healing of tendons, ligaments, muscles, nerves, bones, teeth, corneas, and the endothelium, the lining of blood vessels
available only through 503A compounding or research supply SNRI drugs covered / venlafaxine (Effexor XR) and duloxetine (Cymbalta) Primary interaction concern / overlapping serotonergic and vasopressive effects DDI severity grading / not classifiable (no human PK/PD interaction studies exist) Serotonin syndrome incidence with SNRI monotherapy / estimated 0.07 per 1,000 patient-years per pharmacovigilance data Venlafaxine CYP pathway / CYP2D6 (major), CYP3A4 (minor) Duloxetine CYP pathway / CYP1A2 (major), CYP2D6 (moderate) BPC-157 CYP interaction profile / unknown in humans
doi: 10.1111/j.1349-7006.2009.01131.x 140 YuRWangDRenXZengLLiuY
relevant studies Read below for studies endorsing the use of GHK-Cu
US$ 21.51
US$ 20.25
US$ 29.43
US$ 29.04
US$ 22.71
US$ 27.91
US$ 25.48
US$ 26.15
US$ 21.86
